NASDAQ · ICPT
Healthcare · Biotechnology
$19.00
Up+$0.04 (+0.21%)
Updated Sep 17, 2026, 11:21 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ICPT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ICPT.
ICPT research
Company profile and research snapshot.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 27, 2023 | RBC Capital | Sector Perform | — |
| Sep 27, 2023 | B. Riley Securities | Neutral | — |
| Sep 27, 2023 | HC Wainwright & Co. | Neutral | — |
| Sep 27, 2023 | Canaccord Genuity | Hold | — |
| Aug 3, 2023 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
reuters.com · Sep 11, 2025
Intercept Pharmaceuticals said on Thursday it is voluntarily withdrawing its liver disease treatment from the U.S. market following a request from the Food and Drug Administration.
GlobeNewswire Inc. · Nov 8, 2023
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ICPT.
No results
No recent SID articles mention ICPT.
